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A novel frameshift mutation induced by an adenosine insertion in the
polycystic kidney disease 2 (PKD2) gene. Autosomal dominant polycystic
kidney disease (ADPKD) is one of the most common Mendelian disorders
and is genetically heterogeneous. Linkage studies have shown that the
majority (;85%) of ADPKD cases are due to mutations in PKD1 on
chromosome 16p13.3, while mutations in PKD2 on chromosome 4q21-q23
are thought to account for most of the remaining cases. In this report, we
describe the mutation in a large four-generation ADPKD family (TOR-
PKD77) which we had mapped to the PKD2 locus by linkage analysis. In
this family, we screened for mutations by directly sequencing two nested
RT-PCR fragments (PKD2N1 and PKD2N2) that cover ;90% of the
PKD2 open reading frame. In the affected members, we identified a novel
single adenosine insertion (2160InsA) in the PKD2N2 fragment. This
mutation occurred in the polyadenosine tract (nt2152-2159) of exon 11
and is predicted to result in a frameshift with premature translation
termination of the PKD2 product, polycystin 2, immediately after codon
723. The truncated polycystin 2 is predicted to lack the calcium-binding
EF-hand domain and two cytoplasmic domains required for the ho-
modimerization of polycystin 2 with itself and for the heterodimerization
of polycystin 2 with polycystin 1.
Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common Mendelian disorders and affects approx-
imately 1 in 1,000 live births [1, 2]. Clinically, it is characterized by
progressive formation and enlargement of cysts, typically leading
to end-stage renal disease (ESRD) in late middle age. Overall,
ADPKD accounts for about 5 to 10% of ESRD [1, 2]. The findings
of extra-renal cysts together with increased incidence of mitral
valve prolapse, inguinal hernia, colonic diverticulae, and intracra-
nial arterial aneurysms suggest that ADPKD is a systemic disease
of connective tissue [1].
ADPKD is genetically heterogeneous [1–6]. Linkage studies
have shown that the majority (;85%) of ADPKD cases are due to
mutations in PKD1 on chromosome 16p13.3, while mutations in
PKD2 on chromosome 4q21-q23 are thought to account for most
of the remaining cases [3, 4]. Recently, a small number of families
have been reported to be unlinked to both the PKD1 and PKD2
loci, suggesting the existence of at least one more locus (PKD3) [5,
6]. Locus heterogeneity is now known to contribute to the
differences in disease severity in ADPKD, with PKD1-linked
families having more severe disease. The mean age of onset of
ESRD among affected members from PKD1-linked families is 56
years. In contrast, the mean age of onset of ESRD among affected
members from PKD2-linked families is 70 years [3, 4].
Both PKD1 and PKD2 have been cloned recently [7–9]. For
PKD1, mutation screening has been difficult due to its size (that is,
;13 kb of open reading frame) and complexity (;75% of the
gene is duplicated) [7, 8]. So far, ;25 different mutations in the
unique and part of the duplicated regions of PKD1 have been
reported from the 15 to 20% of patients being screened [10–16].
In comparison, PKD2 is a single copy gene with an open reading
frame of ;3 kb [9]. However, PKD2 mutations are less common,
and only four have been described to date [9, 17]. Here, we report
a novel mutation resulting from a single adenosine insertion in the
polyadenosine tract of exon 11 in PKD2.
METHODS
Clinical ascertainment and sample collection
Seventeen members (i.4. III:3, III:11-14, IV:1-11, IV:13) of the
TORPKD77 family were recruited in the present study (Fig. 1).
For those members known to be affected with ADPKD, their
diagnosis was confirmed by reviewing their clinical records. All
other members (including spouses) whose affection status was
unknown underwent a screening ultrasound. In addition, infor-
mation with respect to the deceased members of the family (such
as age at death, affectedness status, and requirement of ESRD
treatment) was obtained by interviewing several knowledgeable
family members. Blood samples were obtained from all partici-
pating members and genomic DNA was extracted from peripheral
blood lymphocytes by the salting-out method [18]. Total RNA was
extracted from peripheral blood lymphocytes of an affected
(IV:10) and an unaffected member (III:12) [19]. The research
protocol used in the present study was reviewed and approved by
the Human Subject Review Committees at the University of
Toronto.
Key words: Mendelian disorder, family genetics, cyst enlargement, end-
stage renal disease, mutation in PKD2.
Received for publication August 23, 1997
and in revised form November 26, 1997
Accepted for publication November 27, 1997
© 1998 by the International Society of Nephrology
Kidney International, Vol. 53 (1998), pp. 1127–1132
1127
Genotyping and linkage analysis
Genotyping of PKD1 (that is, KG8, I42P, and D16S291) and
PKD2 (D4S1563, and SPP1) markers was performed using pub-
lished methods [9, 13, 20, 21]. All markers are dinucleotide repeat
markers except for I42P, which is a VNTR (variable number of
tandem repeat) marker [13]. All dinucleotide repeat markers were
genotyped by 32P a-dCTP labeling of the PCR products and
analyzed after separation by polyacrylamide gel electrophoresis
[9, 20, 21].
Two-point “maximum likelihood” linkage analysis was per-
formed using the FASTLINK suite of programs [22]. Multipoint
analysis was performed using LINKMAP. We used a dominant
model with a disease gene frequency for PKD1 and PKD2 of 0.001
and 0.0002, respectively [5, 21]. Allele frequencies were calculated
from the alleles observed in married-in individuals from the
pedigree using PEDMANAGER, a computer package developed
at the Whitehead Institute (Reeve-Daly MP, unpublished), and
sex average recombination fractions were used. Lod scores were
calculated at the known recombination fractions between markers
and either PKD1 or PKD2 locus. Age-dependent penetrance was
incorporated using four liability classes assigned to unaffected
individuals, with penetrances of 0.5, 0.7, 0.95, and 0.99 for
members over age 20, 30, 50, and 55 years, respectively [23].
PKD2 mutation screening
To screen for PKD2 mutation, two nested RT-PCR fragments
(PKD2N1 and PKD2N2), which covered 90% of the PKD2 coding
sequence (nt 367-3020), were amplified from the cDNA of an
affected and an unaffected individual, and then sequenced di-
rectly. Reverse transcription for first strand cDNA synthesis was
performed in a 20 ml reaction with 2.5 mg of total RNA, oligo (dT)
primers, and Superscript II (GibcoBRL) at 42°C, according to the
manufacturer’s instructions. Reverse transcription-polymerase
chain reaction (RT-PCR) was performed in a 50 ml reaction using
the Expandy Long Template PCR system (Boehringer Mann-
heim, Mannheim, Germany). The primers for the first round
template (PKD2X) and the nested fragments (PKD2N1 and
PKD2N2), and their annealing temperatures are shown in Table
2. Buffer 1 with the addition of 5% DMSO was used and all PCR
was performed with “hot-start.” Direct sequencing of the PCR
products were performed on both strands using the fluorescent
dideoxy terminator method and analyzed using an ABI 373 DNA
sequencer (Applied Biosystems). The primers used for sequenc-
ing are shown in Table 2.
Allele specific oligonucleotide hybridization
Segregation analysis of the mutation with ADPKD was per-
formed by amplifying the genomic region containing the muta-
tion, and then the PCR products were analyzed by allele specific
oligonucleotide (ASO) hybridization. The primers used for the
genomic PCR were: IF10: 59-AAACCAAGTCTTTTATTTTT-
TCTC-39 and IR11: 59-GGGCTAGAAATACTCTTATCACC-39.
The PCR products were first denatured and then blotted in
duplicate on to two Hybond-N1 membranes. Two oligonucleo-
tide probes [that is, wild-type (W): 59-ACTGAAAAAAAATAC-
CGTG-39 and mutant (M): 59-CTGAAAAAAAAATACCGTG-
39] encompassing the site of mutation were end-labeled with 32P-g
ATP by T4 polynucleotide kinase. Each probe was separately
hybridized to one membrane in 5 3 SSC/53 Denhardt’s solution/
0.5% SDS at 45°C for one hour. Each membrane was then washed
with 2 3 SSC/0.1% SDS for 10 minutes each at room tempera-
ture, at 52°C, and at 54°C, and exposed for autoradiography.
RESULTS
Figure 1 shows the TOR-PKD77 pedigree. The proband (IV:
10) was a 56-year-old female found to have ADPKD by ultra-
sound screening, but was otherwise asymptomatic. Three affected
members (III:2, III:9, III:11) from her family had developed
ESRD and five other affected members (II:2, II:3, II:5, III:4,
III:16) died with less severe disease without requiring dialysis. The
mean age at ESRD or death in these eight affected individuals
was 74 years (95% confidence interval, 69 to 80 years). Two other
affected members (III:13 and III:14) have moderate renal insuf-
ficiency with creatinine clearances in the 40 to 60 ml/min range at
age 81 and 86 years. None of the affected members from the
fourth generation has impaired renal function. Most of the
Fig. 1. Pedigree structure of TOR-PKD77.
Circles represent females, and squares
represent males. All affected individuals are
indicated by blackened symbols, all unaffected
individuals are shown in open symbols, and all
individuals whose affection status is unknown
are shown with (?). A diagonal line through the
symbol indicates the individual is deceased. The
age of death is shown in [ ], and the age at the
last ultrasound is shown in ( ). The proband is
indicated by the arrowhead.
Table 1. Results of pairwise linkage analysis of ADPKD with markers
at PKD1 and PKD2 loci
Lod score at recombination fraction (u) of:
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
PKD1 markers:
ADPKD vs.
KG8 21.60 20.92 20.36 20.15 20.02 0.00 0.00 0.00
142P 23.22 22.17 20.98 20.51 20.11 20.02 0.04 0.00
D16S291 25.60 24.74 22.80 21.69 20.72 20.29 20.09 0.00
PKD2 markers:
ADPKD vs.
D4S1563 0.21 0.20 0.18 0.15 0.090 0.04 0.02 0.00
SPP1 4.55 4.47 4.12 3.67 2.72 1.71 0.72 0.00
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affected members also had liver cysts on ultrasound. There was no
history of ruptured intracranial arterial aneurysm in this family.
We genotyped three polymorphic markers at the PKD1 locus.
Both KG8 and I42P are intragenic markers of PKD1 [13, 20],
while D16S291 is a marker within ;0.2 cM from PKD1 [20]. All
three markers gave negative lod scores (Table 1). Multi-point
linkage analysis using these three markers yielded a lod score of
24.53 with an exclusionary interval of 5 cM, thus excluding linkage
of this pedigree to PKD1. We also genotyped two other markers,
D4S1563 and SPP1, which are within 1 cM telomeric and centro-
meric from PKD2, respectively [9, 21]. While D4S1563 was not
very informative in this family, SPP1 provided strong evidence
supporting linkage of the disease locus in this family to PKD2
(Zmax 5 4.55, u 5 0.00; Table 1). In addition to the linkage results,
the mild disease observed in the older affected members further
supported that this family was PKD2-linked [3, 4]. We therefore
proceeded to screen for mutations in PKD2.
Two nested RT-PCR fragments [PKD2N1 (nt 367-1621) and
Fig. 2. Sequence tracings of genomic PCR products showing the TOR-PKD77 PKD2 mutation. The sequence of the normal allele is shown above the
electropherograms of the control (Ct; III:12) and patient (Pt; IV:10) samples, while the mutant sequence is shown below the patient tracing. The patient
sample reveals a heterozygous mutation for a single adenosine insertion at nucleotide 2160 immediately after the polyadenosine tract (nt 2152-2159)
on exon 11. This mutation is predicted to result in a frameshift with premature translation termination of polycystin 2, immediately after codon 723
(amino acid codes are: K, lysine; N, asparagine; T, threonine; V, valine; D, aspartic acid; Y, tyrosine; R, arginine; G, glutamine; X, stop codon).
Table 2. Oligonucleotide primers used for RT-PCR and sequencing
Name Sequence (59-39)
Annealing
temperature °C
Position of PCR
product nt
PCR product
size kb
RT-PCR primers
PKD2X(F) TCCCCTTCTCCTCCGCTCTC 60 [286-3033] ;2.75
PKD2X(R) CAGCAATTCAGGACAGCCACTTC
PKD2N1(F) GAGGAGGTGGAAGGGGAAGAA 64 [367-1621] ;1.25
PKD2N1(R) CTGACAGCACAACGATCACAACA
PKD2N2(F) GTGGTCAGGTTATTGGTTGAA 56 [1378-3020] ;1.64
PKD2N2(R) CAGCCACTTCCTCACTTATTAGA
Position of sequencing
Primer (nt)
Sequencing primers
PKD2N1(F) GAGGAGGTGGAAGGGGAAGAA [368-397]
PKD2S1(F) CGGATGATGTCACAGCTCTTCCTA [817-840]
PKD2S2(R) CATCCAATAAGGAGCCTTCTGTGA [911-934]
PKD2S3(F) GTGGTCAGGTTATTGGTTGAA [1378-1398]
PKD2S4(R) CTGACAGCACAACGATCACAACA [1599-1621]
PKD2S5(F) CTGACTTGGCACAGCAGAA [2132-2150]
PKD2S6(R) GCCTCAATCTCTGCATCAGTA [2316-2336]
PKD2S7(F) GAGCATTCCATCGGCAGCATA [2614-2634]
PKD2N2(R) CAGCCACTTCCTCACTTATTAGA [2998-3020]
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PKD2N2 (nt 1378-3032)], which contained 90% of the open
reading frame of PKD2, were amplified from the cDNA of the
proband (IV:10) and an unaffected member (III:12). Both RT-
PCR products were sequenced directly. No mutation was detected
in the PKD2N1 fragment. In contrast, electropherograms of the
PKD2N2 fragment from the proband revealed a single adenosine
insertion at nucleotide 2160 immediately after the polyadenosine
tract (nt 2152-2159) on exon 11 of PKD2 [20]. This mutation was
confirmed by re-sequencing exon 11 from RT-PCR products on
the non-coding strand and from the genomic template. This single
base insertional mutation is predicted to result in a frameshift
with premature translation termination of polycystin 2, immedi-
ately after codon 723 (Fig. 2). To further assess the segregation of
this mutation with ADPKD in the TOR-PKD77 pedigree, we
amplified exon 11 from genomic DNA in all study subjects and
from 40 normal Caucasian controls, and analyzed the PCR
products by allele-specific oligonucleotide hybridization. These
data confirmed that all the affected subjects, but none of the
spouses and at-risk escapees of age $ 50 years, were heterozygous
for the 2160InsA mutation (Fig. 3). The 2160InsA mutation was
absent from all 80 normal chromosomes.
DISCUSSION
In the present study, we detected a novel frameshift mutation
due to a single adenosine insertion (2160InsA) in the polyade-
nosine tract (nt 2152-2159) of exon 11 of PKD2 [24]. Simple
sequence repeats, consisting of repeating units of one to five base
pairs, are abundant and highly dispersed in the eukaryotic ge-
nomes [25, 26]. Many of these simple sequence tracts are also
highly polymorphic and recent studies suggest that they are prone
to mutations by “slipped strand mispairing” [25–27]. This may
occur when the normal pairing between the two complementary
strands is altered by staggering of the repeats on the two strands,
leading to incorrect alignment of the repeats. Upon DNA repli-
cation, small insertions or deletions may result that can then be
passed on to the germline [26, 27]. Thus, “slipped strand mispair-
ing” of the polyadenosine tract in exon 11 of PKD2 may provide
a plausible mechanistic explanation for the observed mutation.
The predicted PKD1 product, polycystin 1, is a large glycopro-
tein that contains several extracellular motifs indicative of a role
in cell-cell or cell-matrix interaction [7, 8]. In contrast, the
predicted product of PKD2, polycystin 2, shares some homology
with the a1E-1 subunit of a voltage-activated calcium channel and
is suggested to function as a channel by complexing with another
protein, such as with polycystin 1 or with itself [9]. The mutation
we described here is predicted to produce a truncated polycystin
2 lacking the EF-hand domain, resulting in a protein that would
not bind calcium (Fig. 4). Moreover, recent studies have shown
that polycystin 2 indeed heterodimerized with polycystin 1 and
homodimerized with itself through two distinct C-terminal cyto-
plasmic domains [28, 29]. These interactions suggest that both
polycystin 1 and 2 may function through a common signaling
pathway that is essential for normal tubulogenesis. The same
mutation is also predicted to produce a truncated protein lacking
both the cytoplasmic domains required for polycystin 2 to interact
with polycystin 1 and with itself [9, 28, 29]. Disruption of these
interactions resulting from this mutation can conceivably be the
basis for the cystic disease. Finally, frameshift mutations such as
the one we described here can affect the stability of mutant
mRNA and reduce the steady-state levels of PKD2 mRNA and
protein [26].
Of the 25 different mutations reported in the unique region and
part of the duplicated region of PKD1, most of them are nonsense
and frameshift mutations [10–16]. In comparison, three nonsense
and two frameshift (including that in the current report) muta-
tions have been described for PKD2 to date [9, 17]. In this limited
data set, no clear mutation hot spot is apparent. Most of the PKD1
and PKD2 mutations reported would be predicted to result in
premature translational termination and the production of a
truncated protein [9–17]. It remains speculative whether these
mutations will result in a loss of function or dominant negative
effect [2, 16]. However, two recent reports have documented loss
of heterozygosity at the PKD1 locus in cystic epithelia and suggest
that cystogenesis in ADPKD results from the inactivation of both
alleles of PKD1 from germline and somatic mutations [30, 31].
These data provide strong evidence favoring that most mutations
in PKD1 and perhaps PKD2 may be inactivating. Structure-
function studies of mutations in PKD1 and PKD2 should lead to a
better understanding of the normal functions of these genes, as
well as their role in the pathogenesis of ADPKD.
Fig. 3. Representative results of segregation analysis by allele specific
oligonucleotide (ASO) hybridization. Polymerase chain reaction (PCR)
products amplified from the genomic region containing the PKD2 muta-
tion were denatured and blotted in duplicate on to two Hybond-N1
membranes. ASO hybridization was performed with two oligonucleotide
probes [wild-type (W), 59-ACTGAAAAAAAATACCGTG-39; and mu-
tant (M), 59-CTGAAAAAAAAATACCGTG-39], which detect the nor-
mal and mutant sequence, respectively. The wild-type probe hybridized to
the PCR products from both the affected and unaffected individuals, while
the mutant probe hybridized only to the PCR products from the affected
patients (that is, III:11, III:13, III:14, and IV:3,10).
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